ITGB6 and prostate adenocarcinoma: ITGB6 is a target of intetumumab currently in use for the treatment of prostate adenocarcinoma; additional drugs in use for this gene’s product are abituzumab for metastatic colorectal cancer, and STX-100 for idiopathic pulmonary fibrosis and melanoma Supplementary Material, Table S3.